Posted by Michael Wonder on 10 Nov 2022
Decision to fund vedolizumab for inflammatory bowel disease and brentuximab for rare lymphomas
10 November 2022 - PHARMAC is pleased to announce a decision to fund two new treatments: vedolizumab for inflammatory bowel disease and brentuximub vedotin for rare lymphomas through a supply agreement with Takeda.
In summary:
- Vedolizumab (Entyvio) will be funded for the treatment of patients with inflammatory bowel disease (ulcerative colitis or Crohn’s disease) that has not responded to prior treatments, from 1 February 2023.
- Brentuximab vedotin (Adcetris) will be funded for the treatment of patients with Hodgkin lymphoma and anaplastic large cell lymphoma that has relapsed or not responded to treatment.
